|
Esperion Therapeutics Inc (NASDAQ: ESPR) |
|
Esperion Therapeutics Inc
ESPR's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Esperion Therapeutics Inc 's sales fell
by -52.81 % in the first quarter of 2025 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 3.97 %
Esperion Therapeutics Inc faced net loss in contrast to the net income a year ago in first quarter of 2025
• More on ESPR's Growth
|
|
Esperion Therapeutics Inc realized a net loss in trailing twelve months.
Esperion Therapeutics Inc realized cash reduction of $ -0.57 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.59.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.11.
• More on ESPR's Valuation
|
|
|
|
|
Esperion Therapeutics Inc realized net loss in trailing twelve months.
Esperion Therapeutics Inc realized cash outflow of $ -0.57per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.59.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.11.
• More on ESPR's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com